Officers
Dr Gary Pitcairn
GRP Consulting
DDL Conference Chair
Gary is an experienced senior leader, with a successful track record of leading global multidisciplinary teams, including line management responsibility and budget accountability, within a dynamic R&D organisation.
He is a recognised expert in inhaled drug delivery, with extensive device experience (DPI, pMDI and nebuliser), with proven product development experience, from preclinical through to late phase, including FDA interactions leading to NDA submissions.
Prof. Dr. Regina Scherließ
Kiel University
DDL Conference Vice Chair
Prof. Dr. Regina Scherließ (*1979) is a pharmacist and did her PhD in 2008 on “Formulation of inhalation combination products by co-precipitation”. She then started her own research group working on “Formulations for mucosal vaccination” in the Department of Pharmaceutics and Biopharmaceutics at Kiel University, Germany. During her work she performed research stays in the US, New Zealand and Australia. She received several young researcher awards including The Pat Burnell New Investigator Award 2010 and finished her “Habilitation” in 2015. Her research interests include disperse systems and nanoparticles, stabilization of biomolecules in spray drying and formulations for mucosal vaccination with a focus on respiratory (nasal and pulmonary) dry powder delivery. Since September 2017 she is professor for Pharmaceutics and Biopharmaceutics and chair of the Department of Pharmaceutics at Kiel University. As such she heads the research unit in Pharmaceutics and is responsible for all teaching in Pharmaceutics and Biopharmaceutics
Members
Dr. Michelle Dawson
Fortrea
Michelle Dawson is a qualified pharmacist who earned her PhD from the University of Cardiff in 1997, focusing on the re-formulation of MDIs using novel hydrofluoroalkanes. She began her industrial career at Novartis Horsham Research Centre (UK), developing dry powder inhalers. In 1999, Michelle joined GlaxoSmithKline R&D, where she spent over two decades leading formulation development for multiple dry powder inhaler products, from Phase 2b through launch and post-launch commitments.
Following two years as Director of Formulation Development at Pharmaron UK, Michelle moved to Labcorp (now Fortrea) in July 2022. As Senior Director in the Product Development Consulting group, she provides technical and strategic guidance to clients and oversees program leadership across all clinical phases.
Professor Ben Forbes
King's College London
Ben Forbes is Professor of Pharmaceutics at King’s College London. He has a BPharm from King’s College London (1987) and a PhD in Drug Delivery from Strathclyde University (1996). Before doctoral studies, he worked in hospital pharmacy in London and Sydney, and for Inveresk Clinical Research in Edinburgh. Professor Forbes was appointed to the academic staff of King’s College London in 1997. He is a registered pharmacist in the UK. He originated the term ‘Inhalation biopharmaceutics’ to describe the factors that influence the rate and extent of drug absorption from the lungs and has authored many publications in this area, including: (1) inhaled medicine formulation, (2) the development and application of techniques to study respiratory drug transport and metabolism, (3) respiratory toxicology/disease. He is founder and coordinator of the APSGB ‘Drug Delivery to the Lungs’ Network, a UK-based international academia-industry-regulatory group dedicated to pre-competitive collaboration: https://www.apsgb.co.uk/focus-groups/inhaled/
Dr. Will Ganley
University of Bristol & Nanopharm
Will has a PhD in Physical Chemistry and splits his time between the EPSRC Centre for Doctoral Training (CDT) in Aerosol Science at the University of Bristol and Nanopharm. He joined Nanopharm in 2019 where he established the Computational Pharmaceutics group which applies pharmacokinetic simulations alongside statistical and machine learning approaches to the development and regulation of orally inhaled and nasal drug products. Will joined the Aerosol Science CDT in 2025 as the Partnerships Course Manager where he delivers training in aerosol science to public, private and third sector organisations. Will’s research interests lie in the use of digital technologies to the teaching and application of aerosol science. He has authored a number of peer reviewed publications on pharmaceutics, statistics and physical chemistry and has presented his work at numerous international conferences.
Prof. Dr. Ana Grenha
University of Algarve
Ana Grenha has received her PhD in Pharmacy-Pharmaceutical Technology from the University of Santiago de Compostela – Spain in 2007. She is Assistant Professor in Pharmaceutical Technology at the University of Algarve in Portugal since 2007, having received her Habilitation in Pharmaceutical Technology at the University of Lisbon in 2022. She is a Senior Researcher at the Centre for Marine Sciences (CCMAR-UAlg) and an active collaborator of the iMed from the Faculty of Pharmacy of the University of Lisbon, being the PI of the Drug Delivery Laboratory, which is dedicated to the design and development of particulate carriers for drug delivery, with a particular focus on inhalation. The research group is also keen on exploring the potential of natural materials, namely polysaccharides, fostering new applications that benefit from their intrinsic properties. In 2020 she received the Robalo Cordeiro Award from the Portuguese Society of Pneumology, attributed to a scientific project on pulmonary vaccination.
She is a member of the Board of Directors of the Centre for Marine Sciences since January 2018 and is part of DDL Committee since 2019.
David Harris
Cambridge Healthcare Innovations
David is the Chief Technology Officer for Cambridge Healthcare Innovations, who develop novel healthcare and medical products to improve people’s quality of life. David has been working in the field of respiratory drug delivery for over 25 years, so one of the key focus areas for CHI is the improvement of inhaler devices, which are currently difficult to use and deliver inconsistent performance. He is a practicing physicist, who specialises in aerosol science, fluid dynamics and understanding lung function and its application to good inhaler design. He is a visiting lecturer at Kings College London, joined the organising committee in 2013, and enjoys working with those involved in progressing the science of delivering drugs to the lungs.
Yorick Kamlag
AstraZeneca
Yorick Kamlag, is Head RIA CMC projects, Pharmaceutical Sciences at AstraZeneca. In this role he is responsible for the CMC aspects of projects in the early phase respiratory portfolio.
He previously held several positions at Vectura and Zentiva were he was responsible for design and development of robust formulation / manufacturing / analytical processes and technologies of several inhalation products.
He has previously been chair of EPAG and has been a member of the DDL organizing committee for 5 years.
Professor Jenny Lam
University College London
Jenny Lam is a Professor of Pharmaceutics at the UCL School of Pharmacy, University College London. Jenny is a pharmacist by training, and she obtained her MPharm and PhD from The University of Nottingham, UK. In her PhD study, she investigated the use of non-viral vectors for gene delivery. After working in the National Physical Laboratory for a year and a half, Jenny was awarded the Maplethorpe Fellowship, continued her research in nucleic acid delivery in the Department of Pharmacy at King’s College London. She then joined the Department of Pharmacology and Pharmacy in the University of Hong Kong in 2009 and returned to the UK in 2022.
Jenny’s research is focused on the development of novel delivery system for a wide range of therapeutics including small molecules, nucleic acids (especially siRNA and mRNA), peptides and antibodies, with special interest in the use of particle engineering methods to produce inhaled dry powder formulations for the treatment/prevention of respiratory diseases. She is the principal investigator of a number of competitive grants. She has published over 90 peer-reviewed articles and filed a number of patent applications on pulmonary drug delivery systems.
Alison Lansley
University of Brighton
Alison Lansley is a Principal Lecturer in Pharmaceutics at the University of Brighton (UoB). She obtained her degree in Pharmacy and PhD in mucociliary clearance from the UoB and then undertook post-doctoral positions at UCLA (cellular control of ciliary activity) and, subsequently, King’s College London (the use of airway cell lines as drug absorption models of the lung) where she then took up a lectureship. Following a career break, she was awarded a Daphne Jackson Fellowship which she undertook at the University of Sussex before accepting her current position at the UoB. Her research interests include the use of in vivo-reflective in vitro models to study the effect of mucus on drug/particle deposition behaviour and absorption in the respiratory tract, factors affecting mucociliary clearance and inhalation toxicity.
Dr. Snezana Radivojev
Chiesi Farmaceutici
Snezana Radivojev finished her PhD in the field of Inhalation Biopharmaceutics, focused on the establishment of in vitro-in silico correlations,
through the development of novel dissolution, permeation and PBPK models. In addition, she holds the Dipl. -Ing degree in Chemical and Pharmaceutical Engineering
from Graz University of Technology and the BSc and MSc degree in Chemistry (University of Novi Sad).
As a Head of Pharmaceutical Development at G.ST Antivirals GmbH, she spearheaded the development of antivirals as nasal and inhaled formulations.
Most recently, she joined the GTD Department of Chiesi Farmaceutici, as a Senior Analytical Scientist. She is passionate about supporting early career researchers to follow their ideas,
be open to networking and research collaborations. As a creator of Puzzle Science podcast, she facilitates open discussions regarding the current position of academy and industry from diverse stakeholder perspectives.
Alex Slowey
Kindeva Drug Delivery
Alex Slowey is a pharmacist with over 25 years’ experience in the pharmaceutical industry. In May 2020, he joined Kindeva Drug Delivery as a formulation specialist at their inhalation centre of excellence in Loughborough.
Alex is specialised in early phase development activities related to the formulation of new and existing molecules for pulmonary and nasal delivery. He has expertise in a number of key areas, including providing technical and project leadership to development programmes.
Alex’s interests include aerosol science in relation to the formulation of inhalation devices using innovative approaches, with direct application to the delivery of molecules via the pulmonary and nasal routes.
Professor Omar Usmani
Imperial College London
Prof. Omar S Usmani, MBBS PhD FHEA FRCP,
Clinical Senior Lecturer & Consultant Physician in Respiratory & Internal Medicine,
National Heart and Lung Institute (NHLI), Imperial College London & Royal Brompton Hospital
Omar Usmani leads the Clinical Research Group within the Airway Disease Section at NHLI. His clinical research is focussed on asthma, chronic obstructive pulmonary disease (COPD) and chronic cough. His research disciplines are in inhaled drug delivery, lung imaging, small airways pathophysiology, respiratory pharmacology, and digital respiratory health.
He is a Board member of International Society of Aerosols in Research (ISAM), and a steering committee member of the Small Airways Working Group of the World Allergy Organization (WAO). He is also Associate Editor to the journal Respiration and on the Editorial Board of COPD: Journal of the COPD Foundation.
In 2012, Dr Usmani was awarded a UK National Institute for Health Research (NIHR) Career Development Fellowship to investigate the lung deposition of inhaled bronchodilator aerosols of different particle size within the airways of patients with COPD. This is the first time this award category was been given to Respiratory Science research in the UK.
He is currently clinical lead and co-PI at Imperial College on a highly prestigious EU Horizon 20-20 consortium project, myaircoach, focussing on the role of tele-monitoring and e-health in asthma self-management, where the proposal was ranked 4th highest of all 256 submissions to the call.
In 2015, he was awarded one of the highest accolades in aerosol science, the Thomas T Mercer Award from the American Association of Aerosol Research (AAAR) and ISAM, recognising his international research excellence in pharmaceutical aerosols and inhalable materials.
Conference Managers
Sheila Coates
DDL Conference Organiser
Sheila joined The Aerosol Society in 2007 as the Society’s Administrator following many years with The Institute of Chartered Accountants in England & Wales.
Sheila has worked closely with the Aerosol Society and DDL Committees to develop the wide ranging Events offered to its membership and more recently has focused entirely on the DDL Conference helping to increase the audience and exhibitor participation from across the World.
Nikki Coates
DDL Conference Organiser
Nikki joined The Aerosol Society in 2014 as the Society’s Administrator managing the running of the society’s membership, awards and grants and event organisation. Since 2015 Nikki has focused solely on supporting the growing success of the DDL Conference helping to ensure it runs smoothly and effectively and that it continues to develop and encompass all aspects of the inhalation science field.